Imunon Business Summary

Imunon, Inc. (IMNN) is a clinical-stage biotechnology company that operates primarily through a research and development business model, currently generating no commercial revenue as it advances its proprietary non-viral DNA technology platforms. The company’s operations are bifurcated into two primary segments: the TheraPlas® platform, which focuses on DNA-mediated immunotherapies for solid tumors, and the PlaCCine® platform, designed for developing nucleic acid-based vaccines against infectious diseases and cancer. Its lead clinical asset, IMNN-001, is a DNA-based immunotherapy currently in a pivotal Phase 3 trial (OVATION 3) for the localized treatment of advanced ovarian cancer. Imunon competes in the high-stakes oncology and vaccine sectors against direct peers such as PDS Biotechnology (PDSB), Generation Bio (GBIO), and Xilio Therapeutics (XLO). Within this landscape, Imunon distinguishes itself by targeting the tumor microenvironment through localized delivery of IL-12, aiming to minimize systemic toxicity compared to traditional systemic immunotherapies. Originally founded in 1982 as Cheung Laboratories and later known as Celsion Corporation, the company is currently led by President and CEO Dr. Stacy R. Lindborg, who brings nearly 30 years of industry experience from leadership roles at BrainStorm Cell Therapeutics, Biogen, and Eli Lilly. The executive team includes Chief Medical Officer Dr. Douglas V. Faller, a renowned oncologist and former professor at Boston University, and Interim CFO Jeff Church. Dr. Khursheed Anwer, the long-standing Chief Scientific Officer and architect of the TheraPlas platform, is slated for retirement on February 20, 2026, transitioning to a consulting role to ensure scientific continuity. The board is chaired by Michael H. Tardugno, the company’s former CEO, and includes notable industry veterans like Frederick J. Fritz and Dr. Donald Braun. While institutional ownership remains modest, the company maintains significant insider alignment and has historically secured funding through strategic offerings and government partnerships, including support from the U.S. Department of Health and Human Services (HHS).